Ann Henderson Tilton
Neurology with Special Qualifications in Child Neurology · New Orleans, LANPI 1760405609
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $86,702 of the $118,950 with a category attached, or 72.9%. Ipsen Biopharmaceuticals, Inc accounts for 61.6% of it on its own, with 30 other manufacturers making up the rest. Among neurology with special qualifications in child neurology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $489.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$73K
- AbbVie$36K
- Ipsen Innovation$7K
- UCB, Inc.$418
- Biogen$389
- Eisai Inc.$291
- plus $2K from 25 others
Across 16 payments — averaging $2327.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$37K
What the payments were for
- Consulting fees$15,58813%
- Speaking & faculty fees$86,70273%
- Travel & lodging$10,3979%
- Food & beverage$5,8925%
- Education$3710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 54 | $73,248 |
| AbbVie(2 entities) | 53 | $35,835 |
| Ipsen Innovation | 9 | $6,592 |
| UCB, Inc. | 12 | $418 |
| Biogen | 10 | $389 |
| Eisai Inc. | 12 | $291 |
| Sarepta Therapeutics, Inc. | 14 | $277 |
| PTC Therapeutics, Inc. | 13 | $275 |
| Jazz Pharmaceuticals Inc. | 7 | $222 |
| Neurelis, Inc. | 6 | $170 |
| Sunovion Pharmaceuticals Inc. | 10 | $138 |
| Argenx US, Inc. | 1 | $122 |
| Piramal Critical Care | 3 | $102 |
| Catalyst Pharmaceuticals, Inc. | 3 | $93 |
| NS Pharma, Inc. | 5 | $90 |
| Greenwich Biosciences, Inc. | 4 | $82 |
| Genentech, Inc. | 1 | $78 |
| Upsher-smith Laboratories LLC | 3 | $73 |
| Biomarin Pharmaceutical Inc. | 4 | $57 |
| Novartis | 3 | $56 |
| Sanofi | 2 | $49 |
| SK Life Science, Inc. | 2 | $44 |
| Genentech USA, Inc. | 2 | $43 |
| Acadia Pharmaceuticals Inc | 2 | $43 |
| Immedica Pharma US, Inc. | 2 | $41 |
| ITF Therapeutics LLC | 1 | $33 |
| Mallinckrodt Enterprises LLC | 1 | $28 |
| AstraZeneca | 1 | $18 |
| Metacel Pharmaceuticals LLC | 1 | $17 |
| Gilead | 1 | $13 |
| Zogenix Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DYSPORT$79,065
- BOTOX$35,377
- Epidiolex$125
- VYVGART HYTRULO$122
How this compares
$118,950 in reported general payments places this provider in the 95th percentile of 30 neurology with special qualifications in child neurology providers in Louisiana.
See all neurology with special qualifications in child neurology providers in Louisiana →
Other neurology with special qualifications in child neurology in New Orleans
- Joaquin WongNew Orleans$28K
- Allison ConraveyNew Orleans$15K
- David HoughtonNew Orleans$9K
- Jeremy TolerNew Orleans$9K
- Jessica GautreauxNew Orleans$9K
- Daniella MillerNew Orleans$8K
- Maria WeimerNew Orleans$6K
- Rashmi RaoNew Orleans$5K
- Kelly AngelleNew Orleans$3K
- Kayla PenceNew Orleans$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.